We welcome 2020
2020 is here, and so is our first newsletter for the year and for the new decade. The new year has arrived bringing many anticipations and aspirations, and we are hopeful for new accomplishments. We expect another very busy and productive year and all our teams are hard at work to make it successful. As always, we are planning on keeping you posted about our progress throughout this year.
Vielight to Intensify its R&D in 2020
For 2020, Vielight continues to pursue the course of making available photobiomodulation (PBM) devices that are practical and useful in helping to improve lives.
Vielight 2020 Product Development
The product development program is intensifying with new devices being readied for introduction during the first quarter of 2020. Some of these include the first version of the exciting multi-purpose Neuro Pro, a vagus nerve stimulation device and a pain management device. We are also planning to introduce new PBM devices to help with cognition, sports performance and recovery, and meditation. In the meantime, further investments are being made to improve the quality and usability of existing products.
PBM Research
On the research side, much has been said about Vielight exploring the effects of various photobiomodulation parameters on the brain. Particular attention is given to the induction of pulse frequencies. We have published a peer reviewed paper on the effect of delivering gamma oscillations into the brain. We have also presented our findings regarding the effects of delivering beta oscillations. Plans are being put in place for a multi-faceted study to allow us to be even more precise in modulating brain performance.
Clinical Trials
Clinical trials will continue with the investigations of Vielight PBM devices for Alzheimer’s disease and traumatic brain injury. We also expect new clinical studies for post-traumatic stress disorder (PTSD), attention deficit hyperactivity disorder (ADHD) and chronic pain treatment to start soon. Finally, as for performance improvement, a meditation study is expected to start in January 2020.
According to Vielight CEO, Dr. Lew Lim, “There is a lot of investigation activities going on at Vielight. We are laying the groundwork for more. We will announce them at the right time. Our efforts reflect the desire of the Vielight team to learn and to pursue new applications in the use of light energy to improve quality of lives. Expect more exciting things to come out of Vielight in 2020.”
The Daily Telegraph Headlines Vielight Alzheimer Study
As reported by Sarah Knapton, Science Editor of the Daily Telegraph, “Alzheimer’s disease could be reversed by shining light directly into the brain through the nose and skull, scientists believe.
The first major trial to see if light therapy could be beneficial for dementia has just begun following astonishing early results which have seen people regain their memory, reading and writing skills, and orientation.”
The Telegraph article states further, “If successful it would be the first treatment to actually reverse the disease. So far, even the most hopeful drugs, such as Biogen’s aducanumab, have only managed to slow the onset of dementia, and many scientists had given up hope of reversing brain damage once it had already happened.
But a device called the Neuro RX Gamma headset developed by Canadian-based biotech company Vielight may be about to succeed where other drugs have failed.
The device works through a process called ‘photobiomodulation’, where pulses of near-infrared light are directed to parts of the brain known to be damaged or harmed in dementia.”
Our readers should be aware that some statements and claims made in the Telegraph article may not represent the views and opinions of Vielight Inc.
Dr. Nazanin Hosseinkhah joins Vielight
Vielight welcomes Dr. Nazanin Hosseinkhah into its research team. She is the seventh PhD holder in the company. Dr. Hosseinkhah obtained her PhD in Medical Biophysics from the University of Toronto. She also has Master’s Optics and Bachelor’s in Physics. She was trained at Sunnybrook Hospital, Toronto. Furthermore, Dr. Hosseinkhah brings in her knowledge of focused ultrasound and her experience with startup culture.
